Edition:
India

People: Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

18.06USD
12:00am IST
Change (% chg)

$0.03 (+0.17%)
Prev Close
$18.03
Open
$18.04
Day's High
$18.15
Day's Low
$17.71
Volume
14,000
Avg. Vol
44,627
52-wk High
$34.65
52-wk Low
$10.04

Edwards, Martin 

Hr. Martin Edwards is Director of the Company. Dr. Edwards is Senior Partner (part time) at Novo Ventures and previously served as Chair of KalVista when it was a privately held company. He is Chairman of the Board of Directors of Vantia Therapeutics Ltd., and a member of the Board of Directors of Verona Pharma, Nuvelution Pharmaceuticals Inc, Harmony Biosciences Inc, Inozyme Pharma Inc, F2G Ltd, and Karus Therapeutics Ltd. Prior to joining Novo Ventures, Dr. Edwards was the CEO of ReNeuron Holdings, and formerly Corporate VP and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Earlier, he worked for six years in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton, NJ. Dr. Edwards trained in physiology and medicine in Manchester UK. He was elected as a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --